HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

BAY 54-6544

soluble guanylate cyclase activator

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- BAY 54-6544: 2

Experts

1.	Bachman, Tim: 1 article (01/2018)
2.	Baust, Jeffrey J: 1 article (01/2018)
3.	Becker-Pelster, Eva-Maria: 1 article (01/2018)
4.	Bueno, Marta: 1 article (01/2018)
5.	Bullock, Grant C: 1 article (01/2018)
6.	Gladwin, Mark T: 1 article (01/2018)
7.	Hahn, Scott A: 1 article (01/2018)
8.	Mallampalli, Grace M: 1 article (01/2018)
9.	Mathar, Ilka: 1 article (01/2018)
10.	Mora, Ana L: 1 article (01/2018)

Related Diseases

1.	Progeria (Hutchinson Gilford Syndrome) 01/01/2022 - "In summary, BAY 54-6544 treatment improved the vascular function and survival rates in mice with accelerated ageing, which may have implication in prolonging health span in progeria and normal ageing."
2.	Pulmonary Arterial Hypertension 01/01/2018 - "These findings suggest that sGC is oxidized in the pulmonary arteries of transgenic SCD mice, leading to blunted responses to NO, and that the sGC activator, BAY 54-6544, may represent a novel therapy for SCD-associated pulmonary arterial hypertension and cardiac remodeling."

Related Therapies and Procedures

1.	Therapeutics